BioPharm Intl

Our latest survey of #biopharma professionals on #DigitalTransformation in the industry uncovered a hype-actual adoption gap. Get the full industry report at lnkd.in/eeSbk4ba #AI

Earendil Labs secures $787M to advance an AI-driven biologics engine, backed by majors like @sanofi and @pfizer. Will AI transform antibody R&D in oncology and autoimmune care? Get the story here: hubs.li/Q047KzKJ0 #AIinBiologics #Oncology #Biotech #DrugDiscovery

Multispecific antibodies are transforming biologics. Think bispecifics like teclistamab (@JNJNews) for myeloma and trispecifics for Type 2 inflammation (@pfizer). Precision medicine is evolving fast. Explore more: hubs.li/Q047DK9-0 #PrecisionMedicine #Biologics

Explore the latest in biopharma: Series A funding for T-cell engagers and breakthroughs in multi-agonist metabolic therapies. Listen now for insights on next-gen innovation! hubs.li/Q047CtBy0 #BiopharmaInnovation #ImmunoOncology #MetabolicTherapies #TCellEngagers

Breakthrough for type 2 diabetes: @EliLillyandCo's retatrutide delivers up to 2% A1C reduction and 17% weight loss in 40 weeks. Could triple agonists transform metabolic care? Get the full story: hubs.li/Q047y-qb0 #Diabetes #MetabolicHealth #ClinicalTrials #Innovation

LC-MS and Light-Scattering Methods for Biotherapeutic Development and QC Discover a comprehensive, end-to-end analytical approach for biotherapeutic characterization—from early development through QC and commercialization. Learn More: hubs.li/Q03-62VV0

#ExcalipointTherapeutics has launched with a $68.7M seed round to advance next-gen T-cell engager platforms for solid tumors and autoimmune disease. Get the story: hubs.li/Q047kCzL0 #ImmunoOncology #BiotechInnovation #TCellEngagers #VentureCapital

Breakthrough in gastric & GEJ cancer: Imfinzi (durvalumab) + FLOT is now the first perioperative immunotherapy approved in the EU, showing EFS & OS gains. Get the full story at hubs.li/Q0477FKq0 #Immunotherapy @EU_Commission @AstraZeneca #Oncology #GastricCancer #Imfinzi

Middle East conflict is disrupting cancer drug access as major pharma and logistics teams (e.g., @DHLGlobal, @Kuehne_Nagel) race to reroute vital oncology therapies. Get the story: hubs.li/Q046_5SG0 #PharmaSupplyChain #OncologyDrugs #GlobalHealthCrisis

Discover how late-stage clinical evidence is driving expansion of IL-23 biologics into new inflammatory diseases. Tune in to today’s BioPharm Brief podcast: hubs.li/Q046_p1x0 #Immunology #Biologics #IL23 #PsoriaticArthritis #Ilumya #ImmunologyInnovation

@SunPharma_US’ Ilumya (tildrakizumab-asmn) shows promise in PsA with strong Phase III data. Could FDA approval redefine PsA care? Explore the story: hubs.li/Q046XrKD0 #PsoriaticArthritis #Ilumya #Rheumatology #FDA

What if you could streamline microbial development without compromising scalability? Learn how innovative technology is helping teams reduce process complexity and move more efficiently toward cGMP-ready manufacturing. Save your spot: hubs.li/Q044PGDf0

Immune-evasion breakthrough: Shilpa Biologicals & @mabtree earn @US_FDA orphan drug status for a novel checkpoint inhibitor in rare blood cancers. Read more: hubs.li/Q046Mklv0 #ImmunoOncology #RareBloodCancer #Biologics #FDA

Learn how industry leaders approach challenges, integrate technologies, and advance manufacturing for everything from monoclonal antibodies to next-gen therapies. Register Now: hubs.li/Q044Q8090

#PropancBiopharma advances PRP proenzyme therapy targeting metastatic pancreatic cancer, with #FyoniBio’s PK assay paving the way for Phase Ib trials. Explore this oncology breakthrough: hubs.li/Q046zk8c0 #PancreaticCancer #OncologyInnovation #BiopharmaResearch

@UCBUSA's Bimzelx outperformed @abbvie's Skyrizi in the BE BOLD trial for psoriatic arthritis, hitting ACR50 at Week 16 with no new safety signals. Have you read the story? hubs.li/Q046q5zw0 #PsoriaticArthritis #Rheumatology #Biologics #Immunology

Operations excellence separates good from great in biopharma manufacturing. Learn how to optimize processes, reduce variability, and drive performance with expert insights you can apply across your facility. Save your spot: hubs.li/Q044SnPv0

@biogen’s Phase Ib data: salanersen shows strong motor gains and ~75% NfL drop in SMA kids post-gene therapy. Phase III trials will test annual dosing. How will this impact your SMA strategy? Get the story: hubs.li/Q046nk6X0 #SMA #GeneTherapy #ClinicalTrials #Neurology

Bispecific ADCs like iza-bren are redefining advanced TNBC care, first to show significant PFS/OS vs chemo with dual EGFR/HER3 targeting. How could this shape cancer treatment? Watch: hubs.li/Q046g8350 @bmsnews #SichuanBiokin #SystImmune #BispecificADC #BreastCancer

@JNJNews's Tecvayli (teclistamab) delivers superior PFS & OS in RRMM vs PVd/Kd in Phase III trial, supporting earlier bsAb use. How could this impact your second-line strategies? Full story at hubs.ly/Q046dCHL0 #MultipleMyeloma #Oncology #Immunotherapy #CancerResearch

@BioNTech_Group’s co-founders launch a new biotech to accelerate next-gen mRNA as BioNTech sharpens its oncology focus, aiming for approximately 15 Phase III trials by year-end. Explore the impact: hubs.li/Q046cdGl0 #mRNA #Oncology #BiotechInnovation #CancerResearch